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ABSTRACT
The nuclear receptors are transcription factors involved in the regulation of a variety of physiological processes whose 
activity can be modulated by binding to relevant small molecule ligands. Their dysfunction has been shown to play a 
role in disease states such as diabetes, cancer, inflammatory diseases, and hormonal resistance ailments, which makes 
them interesting targets for drug discovery. The nuclear receptor REV-ERBα is involved in regulating the circadian rhythm 
and metabolism. Its natural ligand is heme and there is significant interest in identifying novel synthetic modulators to 
serve as tools to characterize its function and to serve as drugs in treating metabolic disorders. To do so, we established 
a mammalian cell-based two-hybrid assay system capable of measuring the interaction between REV-ERBα and its 
co-repressor, nuclear co-repressor 1. This assay was validated to industry standard criteria and was used to screen a 
subset of the LOPAC®1280 library and 29568 compounds from a diverse compound library. Profiling of the primary hits in 
a panel of counter and selectivity assays confirmed that REV-ERBα activity can be modulated pharmacologically and 
chemical scaffolds have been identified for optimization.
Keywords: nuclear receptor, REV-ERBα, luciferase reporter, assay development, drug discovery, high throughput 
screening
INTRODUCTION
Nuclear receptors (NRs) are members of a superfamily of ligand-reg-
ulated transcription factors that mediate gene transcription in response to 
endogenous lipophilic small molecules such as steroid hormones, thyroid 
hormones, lipids, fatty acids, and retinoic acids [1]. Since members of 
this superfamily are involved in many physiological processes and play 
an important role in humans, they are a major target class for therapeutic 
intervention to treat human diseases. NRs modulate the transcription of 
their target genes in most instances as a consequence of direct binding 
at specific DNA sequences in the promotor region of their target genes, 
also referred to as response elements (RE) [2]. NRs bind specific DNA 
elements in the regulatory regions of genes via a highly conserved 
DNA binding domain (DBD). Further, they bind specific ligands via 
the ligand binding domain (LBD) that contains a hydrophobic pocket. 
The binding of ligands in the pocket induces conformational changes 
in the receptor that affects the recruitment of co-regulatory molecules 
(cofactors) that stimulate (co-activators) or repress (co-repressors) 
transcription of the target gene [3]. The NRs with unknown ligands 
are referred to as orphan receptors of the superfamily [4]. To date, 48 
NRs are known; however, physiological ligands have been identified 
for only around half of them [5,6].
REV-ERBα and REV-ERBβ are members of the nuclear hormone 
receptor superfamily which are expressed throughout the body [3]. 
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Both receptors have a circadian pattern of expression that is essential to 
circadian and metabolic regulations. REV-ERBα recognizes two classes 
of DNA response elements and can bind to DNA as a monomer, to a 
(A/G) GGTCA half site with a 5’ AT-rich extension or as a homodimer 
to a direct repeat 2 element (AGGTCA sequence with a 2-bp spacer) [3].
Experimental and clinical research has indicated that circadian 
disruption caused in humans by shift work, for example, causes met-
abolic disturbances [7-9]. Genetic ablation of the core CLOCK genes 
in mice leads to a range of abnormal metabolic phenotypes including 
obesity, dyslipidemia, and glucose intolerance, indicating that circadian 
rhythms are linked to the regulation of metabolism [10,11]. Therefore, 
synthetic ligands that modulate REV-ERBα activity may hold utility 
in treatment of several metabolic disorders such as obesity and type 2 
diabetes [12]. Heme binds reversibly to the LBD of REV-ERBα with 
an affinity of 2–4 μM and thereby modulates the ability of the receptor 
to recruit the co-repressor NCoR [3]. This finding has led to the search 
for synthetic REV-ERBα ligands that pharmacologically target the 
circadian rhythm and may hold utility in the treatment of sleep disor-
ders as well as metabolic diseases [13]. The first synthetic REV-ERBα 
ligand to be identified was 1,1-dimethyl-ethyl-N-[(4-chlorophenyl) 
methyl]-N-[(5-nitro-2-thienyl) methyl] glycinate (originally named 
SR6452 and subsequently GSK4112) shown in Figure 1. The compound 
was identified from a fluorescence resonance energy transfer (FRET) 
biochemical screen in which it was shown to increase the interaction 
between REV-ERBα and NCoR in a concentration-dependent manner 
[14]. This non-porphyrin synthetic ligand for REV-ERBα mimics the 
action of heme and behaves as an agonist. In cell-based assays, GSK4112 
was able to reset circadian rhythms [15,16]. However, it displays low 
systemic exposure and weak efficiency as a REV-ERBα agonist. It is 
therefore not suitable for in-vivo experiments [17,18]. Based on the 
GSK4112 scaffold, two other synthetic REV-ERB ligands, SR9009 
and SR9011, have been synthesized (Fig. 1) with improved potency, 
efficacy and pharmacokinetic properties [19]. These compounds are 
synthetic agonists of REV-ERBα and REV-ERBβ and of potential use 
to treat circadian and metabolic disorders [17,19]. In reporter gene 
luciferase assays, SR9009 and SR011 were shown to be 3–4-fold more 
potent than GSK4112 [20].
In the study reported herein, we describe the development of a 
screening compatible mammalian cell-based two-hybrid assay (Fig. 
2) that offers the ability to identify REV-ERBα agonists. The assay 
made use of HEK-293T cells that underwent transfection with plasmids 
including the key target under investigation, namely REV-ERBα. The 
assay was designed to have a dual luminescence readout (firefly and 
Renilla luciferase enzyme activities), as these enzymes allow to con-
struct good dual-reporter assays due to their differences in substrate 
requirements and light output. The assay readout was normalized using 
the Renilla luciferase signal as this takes into account any changes in 
signal due to target-unspecific effects such as growth arrest, cytotoxicity, 
and protein expression manipulation. A number of assay parameters 
were investigated so as to ensure it was miniaturized into 384-well 
microtiter plate format, including optimization of plasmid/DNA, cell 
number, cell culture media components, order of addition of reagents, 
DMSO tolerance, reproducibility, Z' and pharmacology using the avail-
able synthetic ligands (GSK4112, SR9009 and SR011). The validated 
assay was subsequently employed in a high throughput screen (HTS) 
campaign to screen a subset of the Library of Pharmacologically Active 
Compounds (LOPAC®1280, Sigma-Aldrich) as well as 29568 diverse 
compounds from Enamine (Kiev, Ukraine). The smaller screen led to 
the identification of chelidamic acid as a validated hit and the larger 
screen led to the identification of 63 hits of which 48 were confirmed 
in dose-response studies to be REV-ERBα agonists. The confirmed hits 
were evaluated in secondary assays and these scaffolds can be deemed 
as chemical starting points for REV-ERBα agonist drug discovery.
Figure 1. Structural formulae of the synthetic ligands GSK4112, SR9011 and SR9009.
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Figure 2. Schematic depiction of the mammalian cell-based two-hybrid system measuring the interaction between nuclear receptor REV-ERBα 
and corepressor NCoR. Plasmids were co-transfected into HEK-293T cells, and then the Renilla and firefly luciferase signals were quantified using 
the Dual-Glo® Luciferase System 24 h post-transfection. In the mammalian cell-based two-hybrid system, the DNA-binding domain is co-expressed with 
human REV-ERBα and the transcription activation domain is co-expressed with NCoR. The interaction of REV-ERBα and NCoR leads to transcription 
of firefly luciferase. GSK4112 is a REV-ERBα agonist binding to the heme binding site resulting in recruitment of the co-repressor NCoR.
MATERIALS AND METHODS
Materials
Buffers, cell culture media and serum were of the highest quality 
and purchased from Sigma-Aldrich unless otherwise stated. The Library 
of Pharmacologically Active Compounds (LOPAC®1280) was purchased 
from Sigma-Aldrich and 29568 diverse compounds were purchased from 
Enamine (Kiev, Ukraine). All compounds were dissolved in DMSO 
(1 mM solutions LOPAC®1280/2 mM Enamine) and stored at −20°C in 
384-well Labcyte microtiter plates.
Plasmids
Expression vector pGal4-Rev-erbα was created by cloning the human 
REV-ERBα DEF regions in a pGal4 plasmid (pM from Clonetech) which 
contains the Gal4 DBD sequence. The pVP16-NCoR vector corresponds 
to NCoR interaction domain (ID1, ID2, and ID3) sequences fused to 
VP16 transactivation domain cloned into a pcDNA expression vector 
(Life Technologies, CA, USA). The reporter vector contains luciferase 
gene under control of Gal4 response element (UAS) and minimal TK 
promoter sequences [21] and the normalization vector pCMV-Ren 
was from Promega Inc., USA. For the secondary screening assay, the 
pGAL4-hCAR1 expression vector was created by cloning full length 
human CAR1 (NM_005122.4) sequence in the Gal4 plasmid. The pGal4-
hPXR expression vector contains DEF regions of human PXR cloned 
into the Gal4 plasmid [22]. All sequences are available upon request.
After heat shock of competent E. coli XL1 blue cells (Agilent 
Technologies, CA, USA), isolation and purification of plasmids were 
performed using EndoFree (endotoxin free) plasmid purification kit 
(QIAGEN, Hilden, Germany) as instructed by the manufacturer. Re-
striction site analysis was used to confirm each plasmid preparation.
Development and validation of the REV-ERBα mamma-
lian cell-based two-hybrid reporter assay
HEK-293T cells were obtained from DSMZ (German Collection of 
Microorganisms and Cell Cultures, Braunschweig, Germany) and grown 
in DMEM (Lonza Inc., Walkersville, USA) supplemented with 10% v/v 
FBS, 100 μg/ml streptomycin and 100 U/ml penicillin G (Biochrom AG, 
Berlin). The cells were grown at 37°C in a humidified atmosphere in 
the presence of 5% CO2 and only those with passage number of 4–24 
were used for the transfection experiments. Upon growth of the HEK-
293T cells to 80%–90% confluency, the cells were washed with 10 ml 
pre-warmed PBS and detached by incubation for 2–4 min with 3 ml of 
trypsin/EDTA (0.05%/0.02% v/v) at 37°C in the presence of 5% CO2. 
Trypsin was inactivated by addition of 7 ml culture medium. Cells 
were then transferred into culture flask containing fresh pre-warmed 
cell culture medium and split to a 1:10 ratio.
The assay made use of cells cultured as described above which were 
subsequent to harvesting in starvation conditions (medium supplemented 
with DMEM supplemented with 1% DCC FBS, 100 μg/ml streptomycin 
and 100 U/ml penicillin G) and then undergoing bulk transfection by 
the addition of 0.1 µl jetPEI/0.05 µg DNA (0.037 µg p-UAS-TK-Luc, 
0.005 µg Gal4 (NR1D1 or empty), 0.005 µg pNCOR-VP16 and 0.003 µg 
p-Ren) per 20 µl of cells at room temperature for 45 min. This suspension 
was seeded into 384-well assay plates (20 μl/well) (CellStar, white, PS 
Greiner Bio-One GmbH) and grown at 37°C in a humidified atmosphere 
in the presence of 5% CO2 for 6 h. Subsequently, 100 µM GSK4112 
agonist (positive control), test compounds (1 mM stock solutions in 
100% DMSO v/v to give 4 µM final assay concentration), or DMSO only 
(negative control) were added to each well using the Labcyte Echo 550 
(Labcyte, Sunnyvale, CA) acoustic dispenser and incubated for further 
18 h (37°C in a humidified atmosphere in the presence of 5% CO2). 
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Following this, the interaction between REV-ERBα and NCoR was 
investigated using Dual-Glo® Luciferase System using the instructions 
provided by the manufacturer (Promega Inc., USA). Plate handling was 
performed using a Cell Explorer HTS platform (PerkinElmer, Waltham, 
MA), liquid handling was performed using the Multidrop (Thermo, 
Waltham, MA) and luminescence measurements were made using an 
EnVision Multilabel Reader (PerkinElmer, Waltham, MA).
Counter and secondary screening
For counter and secondary screening harvested HEK-293T cells (1 
× 106) were mixed with a mixture of plasmids for counter (p-uas-tk-luc 
1 µg, pCMVRen 0.1 µg, pGal4-Rev-erbα 0.5 µg and pVP16-NCoR 0.5 
µg) and secondary screening assays (p-uas-tk-luc 1 µg, pCMVRen 0.1 µg, 
pGal4-hPXR or pGal4-hCAR1 0.5 µg). The jetPEI transfection reagent 
solution was prepared just before use (5 μl/well). The jetPEI/DNA mix 
was incubated for complex formation at room temperature for 20 min 
and added to the cell suspension. After 24 h incubation, transfected cells 
were seeded on 96-well assay plates (~50000 cells/well) with 10% DCC-
FBS. The following day, cells were treated for 24 h with compounds 
(at 10 µM) or DMSO (0.1% v/v) in phenol red free DMEM with 1% 
DCC-FBS Renilla and firefly luciferase activities were quantified using 
Dual-Glo® Luciferase System using the instructions provided by the 
manufacturer and Victor Light luminometer (PerkinElmer, Waltham, 
MA). For Gal4-hCAR assay, cells were co-treated with an inverse ag-
onist of hCAR1 (PK11195, 10 µM) in order to prevent the constitutive 
activity of the construct.
Data analysis
In order to normalize the raw screening data, the measured relative 
luminesce units (RLU) generated by the converted firefly luciferase 
were divided by the measured Renilla RLU to calculate % Effect within 
ActivityBase XE (ID Business Solutions Ltd, UK) and visualized using 
Spotfire® (PerkinElmer Inc., USA). For dose-response experiments, the 
IC50 values were calculated by fitting the duplicate data to the four-pa-
rameter logistic equation in GraphPad Prism (version 5.02, GraphPad 
Software, Inc., USA) or ActivityBase XE.
RESULTS
Optimization of the REV-ERBα mammalian cell-based 
two-hybrid assay
The development of a cell-based assay for REV-ERBα involved the 
optimization of many variables which were undertaken in a system-
atic manner to yield a reproducible screening compatible assay. The 
optimal jetPEI/DNA known as the N/P ratio (the ratios of moles of the 
amine groups of cationic polymers to those of the phosphate ones of 
DNA), is an important factor that affects the transfection efficiency 
and viability of cells. In order to obtain a positively charged complex 
it is recommended by the manufacturer to use a N/P ratio of > 3. In the 
case of this assay, 0.1 µl jetPEI was shown to yield the highest signal 
(Fig. 3A), with an incubation time with DNA of 45 min that would 
facilitate scheduling of a screening campaign (Fig. 3B). The optimal 
incubation times for the transfection and subsequent addition of com-
pounds were shown to be 6 h and 18 h respectively as these conditions 
yielded IC50 value of 5.5 µM for the reference compound GSK4112, 
which is comparable to those reported in the literature (Fig. 3C). The 
two other known REV-ERBα ligands, namely SR9009 and SR9011 with 
improved efficacy and pharmacokinetic properties relative to GSK4112 
were also characterized in the assay in order to ascertain whether these 
could be more appropriate positive controls in the screening campaign. 
Both SR9009 and SR9011 were associated with a cytotoxic effect at 
high concentrations. Therefore, these were deemed not suitable as a 
potential positive control compound in any screening campaign that 
was intended to be performed. Therefore, as the GSK4112 agonist 
led to the highest increase in firefly luciferase activity (with no effect 
upon the Renilla signal) and thus the highest increase in the interaction 
between REV-ERBα and NCoR, this compound was considered to be 
a potential positive control in subsequent assays.
Cytotoxic effect of DMSO, GSK4112, SR9009 and 
SR9011
The DMSO tolerance of the assay was investigated between 0.1%–5% 
v/v DMSO by addition to non-transfected HEK-293T cells (10000 cells/
well) and incubated for 24 h. The measurement of the cell viability was 
determined using the CellTiter-Glo® assay which measures cellular ATP 
concentrations. DMSO exhibited a slight cytotoxic effect upon the HEK-
293T cells at concentrations > 1% v/v DMSO. The cytotoxic effect of 
GSK4112 was determined by its incubation with non-transfected cells at 
concentrations (up to 200 μM) using the CellTiter-Glo® assay performed 
after 18 h incubation, and no cytotoxic effect was observed. It has been 
recently shown that both SR9009 and 9011 REV-ERB agonists are po-
tential anticancer drugs which presented dose-dependent toxic effects 
on several cancer cell lines [23]. In addition, we have observed that 
these molecules were associated with a decrease in Renilla luciferase 
signal at concentrations as low as 5 µM. Therefore, these compounds 
were not used as reference compounds.
Screening of the REV-ERBα mammalian cell-based 
two-hybrid assay against two compound libraries
In order to verify that the assay performed acceptably under automated 
conditions, a training set of the Library of Pharmacologically Active 
Compounds (LOPAC®1280) was screened. The library was chosen because 
it is commonly employed to validate new drug discovery assays. A total 
of 960 compounds of the LOPAC®1280 library at a final assay concen-
tration of 4 μM were screened in duplicate on different days. The data 
from each plate was normalized using the positive control GSK4112 
(final concentration 100 μM in a complete column) and negative control 
(0.4% v/v DMSO in a complete column). The Z' [24] for each assay 
plate were 0.5, 0.6, 0.6, 0.6, 0.4 and 0.6, giving an average Z' of 0.55 
and a good correlation between the two data sets obtained from two days 
could be observed indicating that the established mammalian cell-based 
two-hybrid assay provided reliable results (Fig. 4A). Compounds which 
showed > 50% activation based on the normalized data and < 50% effect 
of Renilla signal relative to DMSO, highlighted in Figure 4A, were 
defined as hits. The invalidation of cytotoxic compounds based on the 
Renilla signal being < 50% Renilla signal relative to DMSO resulted 
in the identification of 10 non-cytotoxic hits. Chelidamic acid showed 
activity against REV-ERBα in a concentration dependent manner and 
was associated with an EC50 of 0.36 μM (Fig. 4B). No increase in the 
firefly luciferase expression could be detected in the transfected cells 
with an empty vector (Gal4) instead of REV-ERBα plasmid (control 
transfection). This suggested that chelidamic acid binds specifically to 
the LBD site of REV-ERBα receptor leading to increased interaction 
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between the co-expressed proteins REV-ERBα and NCoR resulting in 
an increase of firefly luciferase expression. Hence, chelidamic acid can 
be considered as a validated hit.
A large-scale screen was subsequently performed against 29568 
diverse compounds from the Enamine compound library (Fig. 4C). 
In this case, the positive control, GSK4112 showed throughout the 
screening campaign a high day-to-day, plate-to-plate and also intra-plate 
variability and therefore could not be used as reference for 100% 
activation control and Z' calculation. Instead the quality control was 
solely based on robustness of baseline luminescence intensities and 
plates were considered invalid if absolute counts were significantly 
increased or decreased relative to the general observations caused by 
for example variability in transfection efficiency, and patterns caused 
by technical issues such as mis-dispense and evaporation effects. The 
raw firefly and Renilla luciferase luminescence intensity of all valid 
plates was normalized to the plate average DMSO signal which was set 
to 1. This yielded a homogenous DMSO and mean compound response 
throughout the entire screen. Agonists were characterized by compounds 
that yielded (1) relative Renilla signal within 2 σ of the average DMSO 
relative Renilla signal and (2) relative firefly signal positively exceeding 
the average DMSO relative firefly signal by > 10 σ. Using this criteria, 
63 hits (hit-rate of ~0.2%) were selected of which 15 were antagonist 
hits and 48 were agonist hits. In total, the screening campaign made use 
of 84 plates that were screened over a period of 11 d in batches ranging 
from 5–18 plates and performed with similar quality as the LOPAC®1280 
screen with the hits distributed randomly in each screening batch.
Figure 3. Characterization of the REV-ERBα mammalian cell-based two-hybrid assay. A. Determination of the appropriate DNA to transfection reagent 
ratio (N/P) in the REV-ERBα mammalian cell-based two-hybrid assay. HEK-293T cells (10000 cells/well) were transiently transfected with different amount 
of DNA (0.05–0.3 μg/well) in combination with different jetPEI concentrations (0.1–0.6 μl/well). The Renilla luciferase signal was measured 24 h post 
transfection using the Dual-Glo® Luciferase System. B. Effect of complex formation incubation time on transfection efficiency with jetPEI. HEK-293T cells 
were transfected in suspension with the plasmids in batch mode. The jetPEI reagent was added to DNA sample and the complex was incubated for 5, 15, 
30, 45 and 60 min. The Renilla luciferase signal was measured 24 h post transfection using the Dual-Glo® Luciferase System. C. Dose-response of the 
GSK4112 agonist in the assay. HEK-293T cells were transiently transfected with four plasmids for 8 h followed by stimulation by GSK4112 for 16 h. The 
data were normalized by ratio (firefly luciferase signal/Renilla luciferase signal) and fitted using GraphPad Prism. Calculation of GSK4112 EC50 (5.5 µM) 
and Hill slope (1.21) was performed using GraphPad Prism. Results represent normalized mean values per well (triplicates). Error bars show the STD.
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Confirmation and secondary assays
The activities for three compounds (ENA_T5382514, ENA_T5445822 
and ENA_T5603164) were independently confirmed with similar profiles. 
ENA_T5382514 and ENA_T5445822 increased reporter expression 
compared to control condition (DMSO) with the same efficiency as the 
reference agonist shown in Figure 5A. Conversely the ENA_T5603164 
treatment reduced reporter expression by 45% compared to DMSO 
condition (Fig. 5B) confirming an antagonist profile determined by 
the initial screening. The secondary analysis was designed in order to 
qualify the specificity of molecules initially identified. As many poten-
tial nuclear receptor ligands are susceptible to have off-target effects 
on xenobiotic nuclear receptor (CAR and PXR), it was necessary to 
determine the impact of the identified molecules on these receptors. 
This specificity screening was processed using mammalian single hybrid 
system with a Gal4 fused construct. Indeed, contrary to REV-ERBα 
which interacts only with the corepressor N-CoR, both CAR and PXR 
are able to recruit several endogenous coactivators. Thus, the use of a 
single hybrid system (without co-modulator overexpression) allows the 
assay of ligand activity for CAR and PXR. Both REV-ERBα agonists 
(ENA_T5382514, ENA_T5445822) were also able to activate human 
PXR (Fig. 5C) and therefore their selectivity is limited. In addition, 
ENA_T5445822 seemed to be an activator of human hCAR, conversely 
to ENA_T5603164 which yielded an antagonist profile against this 
receptor.
DISCUSSION
The nuclear hormone receptor REV-ERBα plays an important role 
in the regulation of circadian rhythms of metabolic pathways [25,26]. 
Significant advances have been made recently that aid our understanding 
of how ligands can regulate the nuclear receptor REV-ERBα, which was 
once considered as an orphan receptor [19]. Several studies have led 
to the identification of novel natural (heme) and synthetic (GSK4112, 
SR9009, SR9011) ligands for REV-ERBα that modulate REV-ERBα 
activity in vitro with consequent circadian rhythm delay [13], confirming 
the potential of such ligands to reset the circadian clock after jetlag or 
shift work [27]. As REV-ERBα is involved in lipid and glucose metab-
olism, adipogenesis, and vascular wall physiology, it also represents a 
promising target for the treatment of metabolic abnormalities resulting 
from chronic aberrant circadian rhythm [26,27]. In order to identify fur-
ther agonists for REV-ERBα, a mammalian cell-based two-hybrid assay 
based on the Dual-Glo® Luciferase System was developed, validated, 
and subsequently employed in a HTS campaign to screen a subset of 
the Library of Pharmacologically Active Compounds (LOPAC®1280) as 
well as 29568 diverse compounds from Enamine to identify compounds 
that have the potential to be therapeutics [28].
Figure 4. Screening of a subset of the LOPAC®1280 and diverse Enamine compound libraries. A. Correlation of activation (%) from two inde-
pendent experiments by compounds from the LOPAC®1280 library. The firefly and Renilla luciferase signals were measured using the Dual-Glo® Lu-
ciferase System. The data were normalized by ratio (firefly luciferase signal/Renilla luciferase signal). The average activation (%) based upon the ratio 
firefly luciferase signal/Renilla luciferase signal measured on day 1 and 2 are plotted on the y and x-axes respectively [green: negative control (0.5% 
v/v DMSO); light blue: positive control (100 μM GSK4112); black: test compounds (inactive compounds); purple: hits (active compounds); orange: toxic 
compounds]. B. Dose-response of chelidamic acid in the assay. The data were normalized by ratio (firefly luciferase signal/Renilla luciferase signal) and 
fitted using GraphPad Prism. Results represent normalized mean values per well (triplicates). Error bars show the STD. Calculation of chelidamic acid 
EC50 (0.36 µM) and Hill slope (1.23) was performed using GraphPad Prism. C. Scatter-plot for the screening of the Enamine compound library against 
the REV-ERBα mammalian cell-based two-hybrid assay.
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Figure 5. Secondary screening of selected hits from diverse Enamine 
compound screen. A. Counter screen using mammalian two hybrid assay. 
HEK-293T cell were transfected with Gal4-REV-ERBα and VP16-NCoR as 
described in Figure 1. B and C. Secondary screen assay using a mammalian 
single hybrid assay (without any VP16 construct). B. Cells were transfected 
with Gal4-hPXR. C. Cells were transfected with Gal4-hCAR. Transfected 
cells were treated for 24 h with DMSO (0.1% v/v) or 10 µM of selected 
compounds and luciferase assay were performed as described above. 
Results are expressed as mean ± SEM and statistical significance were 
assessed using GraphPad prism software by a 1-Way ANOVA followed 
by a Tuckey post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001.
The development of the mammalian REV-ERBα cell-based two-hy-
brid assay was a significant challenge as it involved optimization of 
multiple parameters in an iterative manner, which was particularly 
time-consuming. After successful optimization of several parameters 
including the jetPEI/DNA transfection reagent ratio, incubation time for 
the jetPEI/DNA complex formation, cell density, FBS concentration, 
signal window, and DMSO tolerance in an assay volume of 20 μl in 
384-well plate format with an overall assay time of 24 h. Subsequent 
to this, the assay was validated using the synthetic ligand GSK4112 but 
also SR9009 and SR011 to ensure the pharmacology of the assay was 
consistent with values reported in the literature. The assay was shown 
to be particularly sensitive with respect to starvation that made use of 
1% DCC FBS during the assay. The stimulation time by GSK4112 
was shown to be optimal at 16 h, yielding 5.5 μM EC50. These results 
are comparable to those reported in the literature [13]. The Dual-Glo® 
Luciferase System for measuring REV-ERBα activity was particularly 
useful as it enabled the identification of a cytotoxic effect for SR9011, 
in which a decrease in the Renilla signal was observed with increasing 
compound concentration, which excluded this compound for use as a 
genuine REV-ERBα agonist.
Subsequent to the development of the mammalian REV-ERBα cell-
based two-hybrid assay, screening campaigns against a subset of the 
LOPAC®1280 library and 29568 compounds from a diverse compound 
library were successfully accomplished. The hits from each screen 
were profiled in a panel of counter and selectivity assays. These results 
confirmed that REV-ERBα activity can be modulated pharmacologi-
cally and that chemical scaffolds have been identified for optimization. 
A significant amount of experimental work was performed so as to 
optimize the large scale screen and it appears that upon scale-up of the 
assay, although every effort was made so as to ensure the timings for 
each of the critical parts of the assay were kept constant, there does 
appear to be a limit beyond which the assay fails to retain its quality. 
Therefore, the screen was performed by running it in batches of single 
digit plates per run. A general trend that we found was the gradual 
deterioration of assay quality as the number of plates being screened 
were increased. This observation could be due to a number of reasons 
including sensitivity to temperature and CO2, incubator artefacts, liquid 
handling errors and interference from compounds and any similar assay 
that is developed should be appropriately validated prior to embarking 
on a screening campaign [29,30].
The LOPAC®1280 screen led to the identification of a small number 
of hits; amongst them, chelidamic acid (an L-glutamic decarboxylase 
inhibitor) showed activity in a concentration-dependent manner, yielding 
an EC50 value of 0.36 μM. Furthermore, no increase of firefly luciferase 
expression could be detected in the transfected cells with an empty 
vector (Gal4) instead of REV-ERBα plasmid (control transfection). The 
absence of signal increase in the control transfected cells indicated that 
chelidamic acid binds specifically to the LBD site of REV-ERBα leading 
to increased interaction between the co-expressed proteins REV-ER-
Bα and NCoR. Moreover, the compound showed higher activity than 
the previously known agonist, GSK4112. The larger screen led to the 
identification of 63 hits of which 48 were confirmed in dose-response 
studies to be REV-ERBα agonists. The confirmed hits were evaluated in 
secondary assays. Therefore, these scaffolds can be deemed as chemical 
starting points for REV-ERBα agonist drug discovery. The hit rate of 
the assay is acceptable and a number of compounds that were shown 
to be active against other nuclear receptors adds confidence that the 
assay is capable of identifying agonists of this important drug target 
class. This high throughput in vitro screening approach complements 
in silico and low throughput in vitro approaches such as 19F-NMR that 
have previously been employed to identify REV-ERBα modulators [31].
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